Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of rivaroxaban for the prevention of venous thrombembolism after knee arthroscopy

Next Previous
Trial Profile

Efficacy of rivaroxaban for the prevention of venous thrombembolism after knee arthroscopy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ERIKA

Most Recent Events

  • 14 Apr 2016 Results published in the Thrombosis and Haemostasis
  • 14 Apr 2016 Status changed from recruiting to completed, according to the results published in the Thrombosis and Haemostasis.
  • 03 Jul 2013 Planned end date changed from 1 Jan 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top